Sanofi (SNY) and Regeneron (REGN) announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU) indication. Results Confirm Significant Improvement in Itch & Hives The LIBERTY-CUPID C study enrolled CSU patients aged six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with Novartis (NVS) /Roche's (RHHBY) Xolair (omalizumab). Th ...